CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo

Patrick J. Hanley,1,2,3 Jan J. Melenhorst,4 Sarah Nikiforow,5 Phillip Scheinberg,4 James W. Blaney,1 Gail Demmler-Harrison,6 C. Russell Cruz,1,3 Sharon Lam,1,2,3 Robert A. Krance,1,6,7 Kathryn S. Leung,1,6 Caridad A. Martinez,1,6 Hao Liu,1 Daniel C. Douek,8 Helen E. Heslop,1,6,7 Cliona M. Rooney,1,2,6,7,9 Elizabeth J. Shpall,10 A. John Barrett,4 John R. Rodgers,2 Catherine M. Bollard1,2,3,6,7* 1Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital, and Houston Methodist Hospital, Houston, TX 77030, USA. 2 Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA. 3 Program for Cell Enhancement and Technologies for Immunotherapy, The Sheikh Zayed Institute for Pediatric Surgical Innovation, the Center for Cancer and Immunology Research, and the Division of Blood and Marrow Transplantation, Children’s National Health System and The George Washington University, Washington, DC 20052, USA. 4 Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA. 5 Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney St., Boston, MA 02115, USA. 6 Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA. 7 Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA. 8 Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. 9 Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA. 10Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX 77030, USA.